Mindset Pharma Inc. announced that it has filed another provisional patent application with the United States Patent and Trademark Office. Mindset has synthesized several novel tryptamine compounds under its latest patent application, increasing the number of new patent-pending potential drug candidates synthesized under its new drug discovery and development program to an aggregate of 50 drug candidates. Mindset continues to make great progress towards developing a portfolio of novel and patentable next-generation psychedelic drug candidates.